ArticleFrontiers in immunology2025
Two vs three cycles of neoadjuvant immunochemotherapy for resectable non-small-cell lung cancer: a real-world population-based study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Investigation of the Impact of Neoadjuvant Immunochemotherapy Cycles on Pathological Response, Perioperative Safety, and Survival Outcomes in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC). Methods: This study utilized real-world data, focusing on patients with stage IIA-IIIB non-small cell lung cancer (NSCLC) who underwent neoadjuvant immunochemotherapy followed by surgical resection. Subjects were stratified into groups based on whether they received two or three cycles of neoadjuvant therapy. Propensity score matching (PSM) and inverse probability weighting (IPW) analyses were utilized to adjust for covariates, thereby balancing seven clinically relevant variables, including demographic factors, and tumor characteristics, to ensure baseline comparability. Following the application of PSM and IPW, comparisons were conducted between the two-cycle and three-cycle groups in terms of pathological response indicators [pathological complete response (pCR) and major pathological remission (MPR)], perioperative safety metrics, and survival outcomes [overall survival (OS) and disease-free survival (DFS)]. Results: pCR rates were comparable between the three-cycle and two-cycle groups both before adjustment (40.2% vs 42.0%; OR = 0.93, Conclusion: Our analysis demonstrated comparable pathological responses (pCR/MPR) between 2-cycle and 3-cycle neoadjuvant immunochemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.